Arcutis Biotherapeutics, Inc.

This study tested a cream called ARQ-151 in 652 children aged 2 to 5 with eczema. The cream was applied once daily for 4 weeks. The goal was to see if it could clear or nearly clear the skin rash better than a cream with no active ingredient. Results showed that more children usi…

This study looked at the long-term safety of a cream called roflumilast for people with mild to moderate eczema (atopic dermatitis). Over 1,200 participants aged 2 and older applied the cream once daily for up to 52 weeks. The main goal was to track any side effects, and secondar…

This study tested a medicated foam called ARQ-154 on 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug gets into the blood and if it is safe. Children applied the foam once daily for two weeks, and researchers checked for side effect…

This study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to under 2 years with mild-to-moderate eczema. The main goal was to check safety and side effects, not to measure how well it works. The cream is already used in older…